Rapport Therapeutics' official financial statements or SEC filings

Rapport Therapeutics Prices IPO at $17 Per Share for 8 Million Shares, Raises $136 Million

Jun 7, 2024, 12:25 AM

Rapport Therapeutics Inc. (RAPP) has successfully priced its initial public offering (IPO), setting the stage for its debut on Friday. The company priced a full size deal of 8 million shares at $17 each, which is the midpoint of the expected range. The IPO has raised $136 million, and the offering is backed by prominent investors including Johnson & Johnson (JNJ). The pricing of the IPO marks a significant milestone for Rapport Therapeutics as it prepares to enter the public market.